Literature DB >> 27882559

Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs.

Elsa Lilienberg1, Ilse R Dubbelboer1, Erik Sjögren1, Hans Lennernäs1.   

Abstract

OBJECTIVES: In liver cancer treatment, lipiodol is used as a pharmaceutical excipient to improve delivery of the cytostatic drug doxorubicin (DOX). As DOX and its metabolite doxorubicinol (DOXol) cause serious off-target adverse effects, we investigated the effects of drug-free lipiodol or ciclosporin (CsA) on the tissue distribution (Kp ) of DOX and DOXol in relevant pig tissues.
METHODS: Four treatment groups (TI-TIV) all received an intravenous DOX solution at 0 and 200 min. Before the second dose, the pigs received a portal vein infusion of saline (TI), lipiodol (TII), CsA (TIII) or lipiodol and CsA (TIV). After 6 h, the pigs were euthanised, and liver, kidney, heart and intestine samples were collected and analysed. KEY
FINDINGS: The tissue DOX concentrations were highest in the kidney (TI-TIV). All the investigated tissues showed extensive DOX Kp . Lipiodol had no effect on the Kp of DOX to any of the tissues. However, the tissue concentrations of DOX were increased by CsA (in liver, kidney and intestine, P < 0.05).
CONCLUSION: Lipiodol injected into the portal vein does not affect the tissue distribution of DOX and DOXol.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  zzm321990Kzzm321990pzzm321990; ciclosporin; doxorubicin; lipiodol; tissue distribution

Mesh:

Substances:

Year:  2016        PMID: 27882559     DOI: 10.1111/jphp.12665

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  Endovascular Ion Exchange Chemofiltration Device Reduces Off-Target Doxorubicin Exposure in a Hepatic Intra-arterial Chemotherapy Model.

Authors:  Colin Yee; David McCoy; Jay Yu; Aaron Losey; Caroline Jordan; Terilyn Moore; Carol Stillson; Hee Jeung Oh; Bridget Kilbride; Shuvo Roy; Anand Patel; Mark W Wilson; Steven W Hetts
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

2.  Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment.

Authors:  Ilse R Dubbelboer; Erik Sjögren; Hans Lennernäs
Journal:  AAPS J       Date:  2018-08-30       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.